

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Fox Judith A.</u>  (Last) (First) (Middle) SUNESIS PHARMACEUTICALS, INC. 395 OYSTER POINT BOULEVARD, SUITE 400  (Street) SOUTH SAN FRANCISCO CA 94080  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 03/14/2019	3. Issuer Name and Ticker or Trading Symbol <u>SUNESIS PHARMACEUTICALS INC [ SNSS ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chief Scientific Officer	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	40,268	D	

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (Right to Buy)	(1)	11/30/2026	Common Stock	4,000	4	D	
Stock Option (Right to Buy)	(2)	03/31/2027	Common Stock	30,000	4.1	D	
Stock Option (Right to Buy)	(3)	07/10/2024	Common Stock	106	2.62	D	
Stock Option (Right to Buy)	(4)	07/10/2024	Common Stock	12,682	2.62	D	
Stock Option (Right to Buy)	(5)	07/31/2027	Common Stock	10,000	2.64	D	
Stock Option (Right to Buy)	(6)	12/29/2027	Common Stock	195,000	3.69	D	
Stock Option (Right to Buy)	(7)	12/31/2028	Common Stock	150,000	4	D	

**Explanation of Responses:**

- Fully vested.
- One fourth (1/4th) of the shares shall vest one (1) year from the Vesting Commencement Date of March 31, 2017. Thereafter, one forty-eighth (1/48th) of the shares granted shall vest monthly over the next thirty-six (36) months.
- The shares vest monthly over three (3) years from July 10, 2017.
- The shares vest monthly over two (2) years from July 10, 2017.
- One fourth (1/4th) of the shares shall vest one (1) year from the vesting commencement date of July 31, 2017. Thereafter, one forty-eighth (1/48th) of the shares granted shall vest monthly over the next thirty-six (36) months.
- One fourth (1/4th) of the shares shall vest one (1) year from the vesting commencement date of December 29, 2017. Thereafter, one forty-eighth (1/48th) of the shares granted shall vest monthly over the next thirty-six (36) months.
- One fourth (1/4th) of the shares shall vest one (1) year from the Vesting Commencement Date of December 31, 2018. Thereafter, one forty-eighth (1/48th) of the shares granted shall vest monthly over the next thirty-six (36) months.

/s/ Tina Gullotta (Attorney-in-Fact) 03/25/2019

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

POWER OF ATTORNEY

Know all by these presents that the undersigned hereby constitutes and appoints each of Dayton Misfeldt, William P. Quinn, Tina Gullotta and Mehdi Khodadad, signing individually, the undersigned's true and lawful attorneys-in-fact and agents to:

- (1) execute for and on behalf of the undersigned, an officer, director or holder of 10% or more of a registered class of securities of Sunesis Pharmaceuticals, Inc. (the "Company"), Forms 3, 4 and 5 in accordance with Section 16 (a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Forms 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such forms or amendments with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorneys-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact shall no longer be employed by the Company or Cooley LLP, as the case may be.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 21st day of March, 2019.

/s/ Judith A. Fox

-----  
Judith A. Fox